Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Depreciation & Amortization (CF) (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $54000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 38.46% to $54000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $187000.0 through Dec 2025, up 30.77% year-over-year, with the annual reading at $150000.0 for FY2025, 18.11% up from the prior year.
  • Depreciation & Amortization (CF) hit $54000.0 in Q4 2025 for Vistagen Therapeutics, up from $53000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $54000.0 in Q4 2025 to a low of $30600.0 in Q4 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $37326.3 across 5 years, with a median of $34500.0 in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 65.53% in 2021 and later fell 29.98% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $43700.0 in 2021, then fell by 29.98% to $30600.0 in 2022, then grew by 1.31% to $31000.0 in 2023, then increased by 25.81% to $39000.0 in 2024, then surged by 38.46% to $54000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for VTGN at $54000.0 in Q4 2025, $53000.0 in Q3 2025, and $40000.0 in Q2 2025.